secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0000950170-22-025532
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q4 net loss $26.3M, revenue $20.3M; initiates Phase 2 COVID-19 trial
--------------------------------------------------------------------------------

- Q4 royalty revenue $20.3M (down 14% YoY); full year revenue $86.2M vs $97.1M.
- Q4 net loss $26.3M ($1.27 loss per share) vs $24.6M loss ($1.22) prior year.
- Cash $278.5M; expects runway into Q4 fiscal 2024.
- Initiated Phase 2 SPRINT trial of oral 3CL protease inhibitor EDP-235 for mild/moderate COVID-19.
- FY2023 guidance: R&D $210-230M, G&A $46-52M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/enta-20221121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer